Jul 21, 2010
Arzerra Second Quarter 2010 Net Sales Figures

Jul 6, 2010
Genmab Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis

Jul 1, 2010
GlaxoSmithKline and Genmab Announce Amendment to Ofatumumab Agreement

Jun 15, 2010
Genmab announces Change in Management

Jun 7, 2010
Genmab Presents Data from a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients with Refractory Head and Neck Cancer

Jun 2, 2010
Grant of Warrants to Board Members, Management and Employees in Genmab

Jun 2, 2010
Change in Constitution of the Board of Directors

May 28, 2010
Genmab to Present at Three June Investor Conferences

May 11, 2010
Genmab Announces 2010 First Quarter Results

May 10, 2010
Ofatumumab and Zalutumumab Data to be Presented at ASCO

May 7, 2010
Genmab to attend Bank of America Merrill Lynch Forum

Apr 28, 2010
Arzerra First Quarter 2010 Net Sales Figures

Apr 21, 2010
Passing of Genmab A/S’ Annual General Meeting

Apr 21, 2010
Genmab Announces Pipeline and Technology Update

Apr 21, 2010
Annual General Meeting to Proceed as Scheduled

Apr 21, 2010
Constitution of the Board of Directors in Genmab and Grant of Warrants to Employees

Apr 19, 2010
GlaxoSmithKline Receives Conditional Marketing Authorization in the EU for Arzerra (Ofatumumab)

Apr 19, 2010
Genmab Achieves Milestone in Arzerra Collaboration

Mar 25, 2010
Declaratory Relief Complaint for Patent Infringement under Patent based on Manufacture, Marketing and Sale of Arzerra

Mar 24, 2010
Genmab A/S summons Annual General Meeting

Mar 11, 2010
Genmab to attend Kempen & Co Life Sciences

Mar 8, 2010
Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients

Mar 2, 2010
Genmab Announces Year End 2009 Financial Results

Feb 4, 2010
Arzerra 2009 Net Sales Figures

Feb 4, 2010
Genmab Outlicenses Zanolimumab to TenX Biopharma

Feb 3, 2010
Major Shareholder Announcement

Jan 22, 2010
Arzerra (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia

Jan 18, 2010
Major Shareholder Announcement for Genmab A/S